NASDAQ · BNTC
Benitec Biopharma Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for BNTC: Nov 13, 2026
Benitec Biopharma Inc. Common Stock is estimated to report earnings on 11/13/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.3. The reported EPS for the same quarter last year was $-0.22.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.30 | $-0.28 | $-0.34 | 3 |
| Dec 2026 | $-0.31 | $-0.28 | $-0.34 | 3 |
| Mar 2027 | $-0.34 | $-0.29 | $-0.38 | 3 |
| Jun 2027 | $-0.34 | $-0.28 | $-0.40 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel · Zacks- RTTNews · Oct 30, 12:56 PM EDTWeekly Buzz: ABBV, PFE Win FDA Nod; ARTV Slashes Jobs; DAVI, SGRY Strike Deals(RTTNews) – The biotech sector stayed active this week, with a mix of regulatory approvals, strategic partnerships, M&A activity, and clinical trial developments.
- Fintel · Oct 28, 1:59 PM EDTBenitec Biopharma Inc. Announces Positive Interim Phase 1b/2a Results for High Dose BB-301Benitec Biopharma Inc. announced positive interim clinical results from its ongoing BB-301 Phase 1b/2a first-in-human study (NCT06185673) for patients treated with high dose BB-301 and continued durable improvements for patients treated with the low dose of BB-301. The study eval
- RTTNews · Oct 28, 10:26 AM EDTBenitec's BB-301 Shows Swallowing Improvements In Phase 1b/2a Muscle Disorder Trial(RTTNews) – Benitec Biopharma Inc. (BNTC) said Wednesday interim Phase 1b/2a results showed swallowing improvements in all nine patients receiving BB-301 for oculopharyngeal muscular dystrophy.
- Zacks · Sep 25, 8:35 AM EDTAfter Plunging 23.9% in 4 Weeks, Here's Why the Trend Might Reverse for Benitec Biopharma (BNTC)Benitec Biopharma (BNTC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- RTTNews · Sep 15, 5:34 AM EDTBenitec Biopharma FY26 Net Loss Widens; BB-301 Interim Data Due In October(RTTNews) – Benitec Biopharma Inc. (BNTC), a clinical-stage biotechnology company, announced financial results for its full fiscal year ended June 30, 2026 and provided an update on upcoming clinical milestones for BB-301, its lead investigational candidate.
- Fintel · May 12, 6:45 PM EDTEvercore ISI Group Initiates Coverage of Benitec Biopharma (BNTC) with Outperform RecommendationFintel reports that on May 12, 2026, Evercore ISI Group initiated coverage of Benitec Biopharma (NasdaqCM:BNTC) with a Outperform recommendation. Analyst Price Forecast Suggests 116.16% Upside
- RTTNews · Mar 9, 4:14 PM EDTBenitec Biopharma Reports Promising Interim Results For BB-301 Gene Therapy In OPMD Trial(RTTNews) – Benitec Biopharma Inc. (BNTC) on Monday, announced encouraging interim results from its Phase 1b/2a clinical study evaluating BB-301, a gene therapy for Oculopharyngeal Muscular Dystrophy.
- RTTNews · Jan 16, 8:58 AM ESTWeekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch(RTTNews) – This week, the biotech sector saw a steady stream of high-impact news, including a major workforce reduction and a fresh round of regulatory clearances spanning diabetes, rare diseases, biosimilars, and women's health technologies.
- RTTNews · Jan 11, 8:50 AM ESTBenitec Biopharma Provides Positive Long-Term Clinical Study Results For BB-301 Phase 1b/2a Trial(RTTNews) – Benitec Biopharma Inc. (BNTC) announced encouraging long-term results from its BB-301 Phase 1b/2a clinical study evaluating BB-301 for the treatment of dysphagia in oculopharyngeal muscular dystrophy (OPMD).
- Zacks · Dec 24, 9:55 AM ESTDoes Benitec Biopharma (BNTC) Have the Potential to Rally 83.87% as Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 83.9% in Benitec Biopharma (BNTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- Zacks · Dec 5, 9:55 AM ESTWall Street Analysts Predict an 87.48% Upside in Benitec Biopharma (BNTC): Here's What You Should KnowThe mean of analysts' price targets for Benitec Biopharma (BNTC) points to an 87.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Zacks · Dec 3, 9:35 AM ESTDown 25.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Benitec Biopharma (BNTC)Benitec Biopharma (BNTC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near t
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Benitec Biopharma Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.